PL3416617T3 - Połączenie środka przeciwalergicznego z antagonistą receptorów muskarynowych i/lub agonistą receptorów dopaminergicznych do zastosowania w zapobieganiu/zatrzymywaniu postępu krótkowzroczności osiowej u człowieka - Google Patents
Połączenie środka przeciwalergicznego z antagonistą receptorów muskarynowych i/lub agonistą receptorów dopaminergicznych do zastosowania w zapobieganiu/zatrzymywaniu postępu krótkowzroczności osiowej u człowiekaInfo
- Publication number
- PL3416617T3 PL3416617T3 PL17710482.5T PL17710482T PL3416617T3 PL 3416617 T3 PL3416617 T3 PL 3416617T3 PL 17710482 T PL17710482 T PL 17710482T PL 3416617 T3 PL3416617 T3 PL 3416617T3
- Authority
- PL
- Poland
- Prior art keywords
- stopping
- human
- preventing
- combination
- muscarinic antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2016A000876A ITUB20160876A1 (it) | 2016-02-19 | 2016-02-19 | Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo |
| PCT/EP2017/053619 WO2017140846A1 (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3416617T3 true PL3416617T3 (pl) | 2025-06-02 |
Family
ID=55948995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17710482.5T PL3416617T3 (pl) | 2016-02-19 | 2017-02-17 | Połączenie środka przeciwalergicznego z antagonistą receptorów muskarynowych i/lub agonistą receptorów dopaminergicznych do zastosowania w zapobieganiu/zatrzymywaniu postępu krótkowzroczności osiowej u człowieka |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200253951A1 (pl) |
| EP (1) | EP3416617B1 (pl) |
| JP (1) | JP2019505542A (pl) |
| KR (1) | KR20180117642A (pl) |
| CN (1) | CN108883060A (pl) |
| AU (1) | AU2017220640B2 (pl) |
| BR (1) | BR112018016845A2 (pl) |
| CL (1) | CL2018002196A1 (pl) |
| ES (1) | ES3009760T3 (pl) |
| HR (1) | HRP20250270T1 (pl) |
| HU (1) | HUE070966T2 (pl) |
| IL (1) | IL260893B2 (pl) |
| IT (1) | ITUB20160876A1 (pl) |
| PL (1) | PL3416617T3 (pl) |
| SG (2) | SG11201806599SA (pl) |
| WO (1) | WO2017140846A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800005599A1 (it) * | 2018-05-22 | 2019-11-22 | Lente a contatto morbida | |
| CN109044965A (zh) * | 2018-10-17 | 2018-12-21 | 广州大光制药有限公司 | 格隆溴铵的眼用药物组合物及医药用途 |
| IL298796A (en) * | 2020-06-02 | 2023-02-01 | Univ Columbia | Methods and compositions for preventing and treating myopia with levocabastine, a selective histamine h1-receptor antagonist, and derivatives thereof |
| CN114558069A (zh) * | 2022-04-06 | 2022-05-31 | 杭州美依生物科技有限公司 | 一种眼部舒缓涂抹液及其制备方法 |
| CN115137314B (zh) * | 2022-09-02 | 2022-11-15 | 首都医科大学附属北京同仁医院 | 近视风险评估方法、装置及穿戴设备 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE147626T1 (de) | 1989-06-21 | 1997-02-15 | Univ Pennsylvania | Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung |
| MXPA06013903A (es) | 2004-05-28 | 2007-01-26 | Schering Corp | Analogos restringidos de himbacina como antagonistas del receptor de trombina. |
| JP4681617B2 (ja) | 2005-01-14 | 2011-05-11 | シェーリング コーポレイション | ヒンバシンアナログの合成 |
| EP2070518A2 (en) * | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
| SG151148A1 (en) * | 2007-10-05 | 2009-04-30 | Singapore Health Services Pte | Method and/or kit for determining response to muscarinic receptor antagonist treatment |
| ITMO20100369A1 (it) * | 2010-12-30 | 2012-07-01 | Enable Innovations Srl | Gamma di prodotti per uso oftalmico. |
-
2016
- 2016-02-19 IT ITUB2016A000876A patent/ITUB20160876A1/it unknown
-
2017
- 2017-02-17 JP JP2018543132A patent/JP2019505542A/ja active Pending
- 2017-02-17 EP EP17710482.5A patent/EP3416617B1/en active Active
- 2017-02-17 HR HRP20250270TT patent/HRP20250270T1/hr unknown
- 2017-02-17 US US15/999,784 patent/US20200253951A1/en not_active Abandoned
- 2017-02-17 AU AU2017220640A patent/AU2017220640B2/en active Active
- 2017-02-17 CN CN201780011993.4A patent/CN108883060A/zh active Pending
- 2017-02-17 SG SG11201806599SA patent/SG11201806599SA/en unknown
- 2017-02-17 PL PL17710482.5T patent/PL3416617T3/pl unknown
- 2017-02-17 KR KR1020187026872A patent/KR20180117642A/ko not_active Ceased
- 2017-02-17 SG SG10202007417SA patent/SG10202007417SA/en unknown
- 2017-02-17 HU HUE17710482A patent/HUE070966T2/hu unknown
- 2017-02-17 ES ES17710482T patent/ES3009760T3/es active Active
- 2017-02-17 BR BR112018016845A patent/BR112018016845A2/pt not_active Application Discontinuation
- 2017-02-17 WO PCT/EP2017/053619 patent/WO2017140846A1/en not_active Ceased
-
2018
- 2018-07-31 IL IL260893A patent/IL260893B2/en unknown
- 2018-08-09 CL CL2018002196A patent/CL2018002196A1/es unknown
-
2023
- 2023-01-12 US US18/096,165 patent/US20230172904A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3416617A1 (en) | 2018-12-26 |
| HUE070966T2 (hu) | 2025-07-28 |
| BR112018016845A2 (pt) | 2018-12-26 |
| IL260893A (pl) | 2018-09-20 |
| EP3416617C0 (en) | 2024-12-18 |
| SG10202007417SA (en) | 2020-09-29 |
| CN108883060A (zh) | 2018-11-23 |
| RU2018133026A3 (pl) | 2020-04-24 |
| CL2018002196A1 (es) | 2019-01-25 |
| AU2017220640A1 (en) | 2018-10-04 |
| EP3416617B1 (en) | 2024-12-18 |
| IL260893B1 (en) | 2023-04-01 |
| IL260893B2 (en) | 2023-08-01 |
| RU2018133026A (ru) | 2020-03-19 |
| CA3013846A1 (en) | 2017-08-24 |
| ITUB20160876A1 (it) | 2017-08-19 |
| HRP20250270T1 (hr) | 2025-04-25 |
| AU2017220640B2 (en) | 2022-08-25 |
| SG11201806599SA (en) | 2018-09-27 |
| JP2019505542A (ja) | 2019-02-28 |
| US20230172904A1 (en) | 2023-06-08 |
| KR20180117642A (ko) | 2018-10-29 |
| WO2017140846A1 (en) | 2017-08-24 |
| ES3009760T3 (en) | 2025-03-31 |
| US20200253951A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273031A (en) | Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine | |
| SG10202007417SA (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| ZA201808186B (en) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
| PT3545948T (pt) | Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma | |
| HUE037558T2 (hu) | Imidazo[4,5-c]kinolin-2-on vegyületek és alkalmazásuk rák kezelésében | |
| CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
| EP3189834A4 (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
| PT3615035T (pt) | Utilização de 20-hidroxiecdisona e os seus derivados no tratamento de miopatias | |
| PL3197429T3 (pl) | Leczenie skojarzone inhibitorami sglt2 i agonistami dopaminy do profilaktyki zaburzeń metabolicznych u zwierząt koniowatych | |
| PL3381451T3 (pl) | Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej | |
| ZA201902873B (en) | Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients | |
| ZA201900861B (en) | Aza¿indazole compounds for use in tendon and/or ligament injuries | |
| SG11201704756YA (en) | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| EP3375781A4 (en) | BENZORING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | |
| EP3509612A4 (en) | CXCR4 ANTAGONISTS AND METHOD OF USE | |
| PT3215143T (pt) | Combinação compreendendo espirulina e palmitoíletanolamida | |
| ZA201901740B (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| IL261645A (en) | History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors | |
| IL261834A (en) | Cd31shed agonists for use in the prevention and/or treatment of reperfusion injury | |
| MX2016016667A (es) | Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. | |
| IL274868A (en) | History of imidazopyridine and their use as medicine | |
| IL267534A (en) | Low dose drug combinations for use in preventing and treating neuronal damage | |
| IL261182B (en) | Leptin antagonist for use in the treatment of ischemia and reperfusion injury | |
| ZA201806864B (en) | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |